文献速递糖尿病

印度2型糖尿病合并抑郁症患者协同照护模式的成本效果

Cost-Effectiveness of a Collaborative Care Model Among Patients With Type 2 Diabetes and Depression in India.
PubMed 文献 · Diabetes Care · 2023-01-01

在印度四家城市诊所开展24个月平行、开放标签、实用性随机临床试验的试验内成本效果分析,404例血糖控制不佳的2型糖尿病合并抑郁症状患者随机接受12个月协同照护后12个月常规照护或24个月常规照护。多支付方视角下协同照护每获得1个QALY额外花费309,558印度卢比(15,344国际元),每获得1个无抑郁日额外花费290.2印度卢比(14.4国际元),意愿支付阈值为每QALY 336,000印度卢比时成本效果概率为56.4%。

要点

  • 多支付方视角下协同照护每QALY增量成本为309,558印度卢比(15,344国际元)。
  • 每无抑郁日增量成本为290.2印度卢比(14.4国际元),成本效果概率>95%的意愿支付阈值为401.6印度卢比(19.9国际元)。
  • 将协同照护整合入临床工作流程可使增量成本降低约47%(ICER 162,689印度卢比/QALY,成本效果概率89.4%)。

核心结论

  • 在印度城市,2型糖尿病合并抑郁症患者的协同照护可能具有成本效果,尤其是整合入临床工作流程时。
  • 长期成本效果可能更有利,但在中低收入国家推广取决于异质性背景因素。

研究设计与样本

  • 研究为在印度四家城市诊所开展的24个月平行、开放标签、实用性随机临床试验的试验内成本效果分析,从多支付方和社会视角进行。
  • 404例血糖控制不佳的2型糖尿病(HbA1c ≥8.0%、收缩压≥140 mmHg或LDL胆固醇≥130 mg/dL)且伴有抑郁症状(9项患者健康问卷评分≥10)的患者随机分配至协同照护组(由非医师照护协调员支持、电子登记和专家支持的病例复核,持续12个月,随后12个月常规照护)或24个月常规照护组。

主要发现

  • 多支付方视角下,与常规照护相比,协同照护每获得1个QALY额外花费309,558印度卢比(15,344国际元),每获得1个无抑郁日额外花费290.2印度卢比(14.4国际元)。
  • 以每QALY 336,000印度卢比(16,654国际元,约为人均国内生产总值的3倍)作为意愿支付阈值时,成本效果概率为56.4%。
  • 每无抑郁日意愿支付阈值为401.6印度卢比(19.9国际元)时,成本效果概率>95%。
  • 社会视角下成本效果略低。
  • 敏感性分析中,将协同照护整合入临床工作流程使增量成本降低约47%(ICER 162,689印度卢比/QALY,成本效果概率89.4%),但调整基线值后成本效果下降。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 社会视角下成本效果略低。
  • 调整基线值后成本效果下降。
  • 在中低收入国家推广取决于异质性背景因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the cost-effectiveness of collaborative versus usual care in adults with poorly controlled type 2 diabetes and depression in India. RESEARCH DESIGN AND METHODS: We performed a within-trial cost-effectiveness analysis of a 24-month parallel, open-label, pragmatic randomized clinical trial at four urban clinics in India from multipayer and societal perspectives. The trial randomly assigned 404 patients with poorly controlled type 2 diabetes (HbA1c ≥8.0%, systolic blood pressure ≥140 mmHg, or LDL cholesterol ≥130 mg/dL) and depressive symptoms (9-item Patient Health Questionnaire score ≥10) to collaborative care (support from nonphysician care coordinators, electronic registers, and specialist-supported case review) for 12 months, followed by 12 months of usual care or 24 months of usual care. We calculated incremental cost-effectiveness ratios (ICERs) in Indian rupees (INR) and international dollars (Int'l-$) and the probability of cost-effectiveness using quality-adjusted life-years (QALYs) and depression-free days (DFDs). RESULTS: From a multipayer perspective, collaborative care costed an additional INR309,558 (Int'l-$15,344) per QALY and an additional INR290.2 (Int'l-$14.4) per DFD gained compared with usual care. The probability of cost-effectiveness was 56.4% using a willingness to pay of INR336,000 (Int'l-$16,654) per QALY (approximately three times per-capita gross domestic product). The willingness to pay per DFD to achieve a probability of cost-effectiveness >95% was INR401.6 (Int'l-$19.9). From a societal perspective, cost-effectiveness was marginally lower. In sensitivity analyses, integrating collaborative care in clinical workflows reduced incremental costs by ∼47% (ICER 162,689 per QALY, cost-effectiveness probability 89.4%), but cost-effectiveness decreased when adjusting for baseline values. CONCLUSIONS: Collaborative care for patients with type 2 diabetes and depression in urban India can be cost-effective, especially when integrated in clinical workflows. Long-term cost-effectiveness might be more favorable. Scalability across lower- and middle-income country settings depends on heterogeneous contextual factors.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Emmert-Fees KMF, Laxy M, Patel SA, et al. Cost-Effectiveness of a Collaborative Care Model Among Patients With Type 2 Diabetes and Depression in India. Diabetes Care. 2023. PMID: 36383487. doi:10.2337/dc21-2533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。